Gossamer Bio暂停三期Seranata研究在Ph-ILD患者中的招募,公司正评估Prosera结果影响

美股速递
Mar 18

Gossamer Bio Inc.宣布,在评估Prosera试验结果对临床项目的影响期间,已暂停针对进行性肺纤维化间质性肺病(Ph-ILD)患者的三期Seranata研究的新患者招募工作。该决定旨在确保临床试验方案与最新数据保持科学一致性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10